In a few diseases, such as for inflammatory bowel disease (IBD), the situation has improved dramatically over the past couple of decades, with an important increase in the amount of IBD patients who're overweight and suffer from being overweight‐linked difficulties. Conclusions: Golimumab won't look able to maintain extensive-term remission in https://www.directivepublications.org/journal-of-digestive-and-liver-diseases/